Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Metformin use and endometrial cancer risk among females with polycystic ovary syndrome
FY 2022-23
Summary
Polycystic ovary syndrome (PCOS) is an endocrine disorder that is estimated to affect up to 20% of females. Females with PCOS have an increased risk of multiple diseases, such as cardiovascular disease, diabetes, and cancer. In particular, they face an almost threefold increase in the risk of endometrial cancer. The symptoms of PCOS are treated with a variety of drugs; however, none have been approved by regulatory agencies specifically for the treatment of PCOS. Metformin is an antidiabetic drug that is commonly used in this population. It has been hypothesized to protect against a variety of cancers in studies of patients with diabetes. The association between metformin and endometrial cancer in females with type 2 diabetes is unclear, and the relationship has not been examined in females with PCOS.
To investigate this question, I will identify a cohort of approximately 300,000 females in the United Kingdom with PCOS. I will then use advanced statistical techniques to assess whether metformin protects against endometrial cancer in this population, and whether the relationship varies by duration of metformin use, age, and other relevant factors. My research will provide a comprehensive overview of a large population of females with PCOS and generate real-world safety information in a cost-effective and timely manner. Assessing the safety of medications used for the management of PCOS is critical so that those affected by the condition can receive safe and effective care.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475816
Name
Shapiro Samantha
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Metformin use and endometrial cancer risk among females with polycystic ovary syndrome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Endocrine Disorders; Epidemiology; Metformin; Pcos; Pharmacoepidemiology; Polycystic Ovary Syndrome
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine disorder that is estimated to affect up to 20% of females. Females with PCOS have an increased risk of multiple diseases, such as cardiovascular disease, diabetes, and cancer. In particular, they face an almost threefold increase in the risk of endometrial cancer. The symptoms of PCOS are treated with a variety of drugs; however, none have been approved by regulatory agencies specifically for the treatment of PCOS. Metformin is an antidiabetic drug that is commonly used in this population. It has been hypothesized to protect against a variety of cancers in studies of patients with diabetes. The association between metformin and endometrial cancer in females with type 2 diabetes is unclear, and the relationship has not been examined in females with PCOS.
To investigate this question, I will identify a cohort of approximately 300,000 females in the United Kingdom with PCOS. I will then use advanced statistical techniques to assess whether metformin protects against endometrial cancer in this population, and whether the relationship varies by duration of metformin use, age, and other relevant factors. My research will provide a comprehensive overview of a large population of females with PCOS and generate real-world safety information in a cost-effective and timely manner. Assessing the safety of medications used for the management of PCOS is critical so that those affected by the condition can receive safe and effective care.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Shapiro, Samantha
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~